tazobactam has been researched along with Infections, Proteus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, RN; Mutnick, AH; Turner, PJ | 1 |
| Amicosante, G; Belloni, R; Bianchi, C; Lombardi, G; Luzzaro, F; Perilli, M; Toniolo, A; Zollo, A | 1 |
| Aronoff, SC; Jacobs, MR; Labrozzi, PH; Yamabe, S | 1 |
3 other study(ies) available for tazobactam and Infections, Proteus
| Article | Year |
|---|---|
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins | 2002 |
Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Drug Resistance, Microbial; Drug Resistance, Multiple; Enzyme Inhibitors; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Proteus Infections; Proteus mirabilis; Tazobactam | 2001 |
Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in mice.
Topics: Amoxicillin; Animals; Bacterial Infections; Citrobacter; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Enterobacteriaceae Infections; Female; Mice; Penicillanic Acid; Proteus Infections; Staphylococcal Infections; Tazobactam | 1986 |